BMGL
Basel Medical·NASDAQ
--
--(--)
--
--(--)
BMGL fundamentals
During FY 2025, Basel Medical (BMGL) reported revenue of 8.90M, a YoY change of 20.00%. Net income was -8.36M, a YoY change of -646.74%. Click to view the full income statement and explore the company's earnings performance.
Income Statement
FY,2022 | H1,2023 | FY,2023 | H1,2024 | FY,2024 | H1,2025 | FY,2025 | TTM |
|---|
Start Date | Jul 1, 2021 | Jul 1, 2022 | Jul 1, 2022 | Jul 1, 2023 | Jul 1, 2023 | Jul 1, 2024 | Jul 1, 2024 | -- |
End Date | Jun 30, 2022 | Dec 31, 2022 | Jun 30, 2023 | Dec 31, 2023 | Jun 30, 2024 | Dec 31, 2024 | Jun 30, 2025 | -- |
Fiscal Year-End | Jun 30 | Jun 30 | Jun 30 | Jun 30 | Jun 30 | Jun 30 | Jun 30 | -- |
Revenue | 7.67M -- | 3.76M -- | 7.17M -6.42% | 3.86M +2.62% | 7.42M +3.38% | 3.68M -4.46% | 8.90M +20.00% | 8.90M -- |
Sales and Services Revenue | 7.67M -- | 3.76M -- | 7.17M -6.42% | 3.86M +2.62% | 7.42M +3.38% | 3.68M -4.46% | 8.90M +20.00% | 8.90M -- |
Other Revenue | -- -- | -- -- | 304.93K -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Cost of Goods and Services | -- -- | -- -- | -- -- | 967.95K -- | -- -- | 768.03K -20.65% | -- -- | -- -- |
Gross Profit | 7.67M -- | 3.76M -- | -- -- | 2.89M -23.14% | -- -- | 2.92M +0.96% | -- -- | -- -- |
Other Operating Income | -- -- | -- -- | -- -- | -- -- | 340.19K -- | -- -- | 1.38M +305.02% | 1.38M -- |
Operating Expenses | 5.72M -- | 3.21M -- | 5.73M +0.13% | 1.47M -54.26% | 5.85M +2.20% | 3.34M +127.22% | 18.81M +221.38% | 18.81M -- |
Selling, General and Administrative Expenses | 3.31M -- | 1.84M -- | 2.81M -15.09% | 1.20M -34.82% | 3.08M +9.32% | 2.34M +95.34% | 5.96M +93.76% | 5.96M -- |
Loss on Impairment of Other Assets | -- -- | -- -- | -- -- | -- -- | 0 -- | -- -- | 8.14M -- | 8.14M -- |
Other Operating Expenses | 2.41M -- | 1.37M -- | 2.91M +21.09% | 270.69K -80.29% | 2.78M -4.68% | 997.26K +268.42% | 4.71M +69.69% | 4.71M -- |
Operating Income | 1.95M -- | 545.99K -- | 1.75M -9.99% | 1.42M +159.99% | 1.90M +8.65% | -422.10K -129.74% | -8.53M -547.93% | -8.53M -- |
Non-Operating Income (Loss) | -230.79K -- | -99.84K -- | -176.44K +23.55% | 49.50K +149.58% | -130.05K +26.30% | 190.33K +284.49% | -160.35K -23.30% | -160.35K -- |
Other Non-Operating Income (Loss) | -- -- | -- -- | -- -- | 2.33K -- | -- -- | 222.00K +9431.09% | -- -- | -- -- |
Net Interest Expense | 230.79K -- | 99.84K -- | 176.44K -23.55% | -47.17K -147.25% | 130.05K -26.30% | 31.68K +167.15% | 160.35K +23.30% | 160.35K -- |
Interest Expense | 230.79K -- | 99.84K -- | 176.44K -23.55% | 72.86K -27.03% | 130.05K -26.30% | 71.45K -1.93% | 160.35K +23.30% | 160.35K -- |
Interest Income | -- -- | -- -- | -- -- | 120.03K -- | -- -- | 39.78K -66.86% | -- -- | -- -- |
Pretax Income From Continuing Operations | 1.72M -- | 446.15K -- | 1.58M -8.17% | 1.47M +229.26% | 1.77M +12.57% | -231.77K -115.78% | -8.69M -589.80% | -8.69M -- |
Income Tax Expense | 293.81K -- | -4.24K -- | 257.55K -12.34% | 463.49K +11037.73% | 244.81K -4.95% | 284 -99.94% | -328.16K -234.05% | -328.16K -- |
Current Income Tax | -- -- | -- -- | 278.99K -- | -- -- | 282.95K +1.42% | -- -- | 0 -100.00% | -- -- |
Deferred Income Tax | -- -- | -- -- | -17.25K -- | -- -- | -36.48K -111.53% | -- -- | 0 +100.00% | -- -- |
Income Tax Adjustments | -- -- | -- -- | -4.20K -- | -- -- | -1.66K +60.44% | -- -- | -328.16K -19648.15% | -328.16K -- |
Net Income | 1.42M -- | 450.39K -- | 1.32M -7.31% | 1.01M +123.26% | 1.53M +15.99% | -232.05K -123.08% | -8.36M -646.74% | -8.36M -- |
Net Income Attributable to Minority Interests | -- -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -393.9 -- | -393.9 -- |
Net Income Attributable to Owners of the Company | 1.42M -- | 450.39K -- | 1.32M -7.31% | 1.01M +123.26% | 1.53M +15.99% | -232.05K -123.08% | -8.36M -646.71% | -8.36M -- |
Net Income Attributable to Common Stockholders | 1.42M -- | 450.39K -- | 1.32M -7.31% | 1.01M +123.26% | 1.53M +15.99% | -232.05K -123.08% | -8.36M -646.71% | -8.36M -- |
Other Comprehensive Income | -- -- | -- -- | -- -- | -- -- | -- -- | -8.86K -- | -- -- | -- -- |
Total Comprehensive Income | 1.42M -- | 450.39K -- | 1.32M -7.31% | 1.01M +123.26% | 1.53M +15.99% | -240.92K -123.96% | -8.36M -646.74% | -8.36M -- |
Total Comprehensive Income Attributable to Owners of the Company | 1.42M -- | 450.39K -- | 1.32M -7.31% | 1.01M +123.26% | 1.53M +15.99% | -240.92K -123.96% | -8.36M -646.74% | -8.36M -- |
Basic EPS | 0.09 -- | 0.03 -- | 0.08 -11.11% | 0.06 +100.00% | 0.1 +25.00% | -0.01 -116.67% | -0.45 -550.00% | -0.45 -- |
Basic EPS from Continuing Operations | -- -- | -- -- | 0.08 -- | 0.06 -- | 0.1 +25.00% | -0.01 -116.67% | -0.45 -550.00% | -0.45 -- |
Diluted EPS | 0.09 -- | 0.03 -- | 0.08 -11.11% | 0.06 +100.00% | 0.1 +25.00% | -0.01 -116.67% | -0.45 -550.00% | -0.45 -- |
Diluted EPS from Continuing Operations | -- -- | -- -- | 0.08 -- | 0.06 -- | 0.1 +25.00% | -0.01 -116.67% | -0.45 -550.00% | -0.45 -- |
You can ask Aime
What factors drove the changes in Basel Medical's revenue and profit?Did Basel Medical beat or miss consensus estimates last quarter?What is the revenue and EPS growth rate for Basel Medical year over year?What does Basel Medical do and what are its main business segments?What guidance did Basel Medical's management provide for the next earnings period?What is Basel Medical's gross profit margin?What were the key takeaways from Basel Medical’s earnings call?What is the market's earnings forecast for Basel Medical next quarter?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
